Welcome to our dedicated page for Assertio Holdings SEC filings (Ticker: ASRT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Assertio Holdings, Inc. (ASRT) provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed information about Assertio’s operations as a pharmaceutical company focused on oncology, neurology, and pain management, and they complement the company’s press releases and investor presentations.
Through this page, readers can review current reports on Form 8-K, where Assertio reports material events such as leadership transitions, executive appointments, supply and licensing agreements, and financial results announcements. For example, recent 8-K filings describe the appointment of a new Chief Executive Officer, the promotion of a President and Chief Operating Officer, and the separation of a former CEO, along with associated management continuity and compensation arrangements.
Filings also document capital markets and listing-related actions, including disclosure of Assertio’s common stock listing on The Nasdaq Stock Market LLC under the symbol ASRT and the implementation of a 1-for-15 reverse stock split of its issued and outstanding common stock. These records provide historical context for Nasdaq listing compliance and changes to the company’s capital structure.
Investors can use Assertio’s SEC filings to understand supply and product agreements, such as amendments to long-term supply contracts for Rolvedon drug substance through its subsidiary Spectrum Pharmaceuticals, Inc., including pricing terms and forecasting obligations. The filings also reference press releases that contain financial results, guidance updates, and strategic commentary.
On Stock Titan, SEC documents are paired with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly identify topics like quarterly performance (10-Q), annual reporting (10-K), and material 8-K events. The platform also surfaces insider and executive-related disclosures, allowing users to follow governance changes and compensation arrangements without reading every line of each filing.
Assertio Holdings, Inc. completed the sale of its INDOCIN, SPRIX, SYMPAZAN, CAMBIA, ZIPSOR and OTREXUP product franchises to Cosette Pharmaceuticals for an upfront cash payment of $35.0 million, plus potential deferred and milestone-based payments. These include up to $32.0 million of net sales-based milestones on SYMPAZAN, OTREXUP and INDOCIN, as well as SPRIX-related contingent payments: $1.0 million for successful quality approval and delivery of a new batch by May 31, 2026, 8% of SPRIX gross profits from April 8, 2026 through December 31, 2027, and $2.0 million if SPRIX 2027 net sales exceed $7.0 million. Cosette assumed certain contracts and obligations related to these products. Pro forma financial statements show 2025 revenues for Assertio’s continuing operations of $68.2 million and a net loss of $31.3 million, illustrating a smaller, continuing business that remains loss-making after the divestiture.
Assertio Holdings, Inc. entered into an Agreement and Plan of Merger providing for a cash tender offer by Audi Merger Sub to acquire all outstanding shares for $18.00 per share plus one non-transferable contingent value right (CVR) per share. The Board unanimously approved the Merger and recommended stockholder tender.
The Offer must commence within ten business days and initially runs for 20 business days. Key conditions include valid tenders exceeding 50% of outstanding shares and Closing Net Cash of at least $115,000,000. The transaction is not conditioned on financing; Parent has related equity and debt commitments and limited guarantees. Separately, Assertio sold specified product franchises to Cosette for $35,000,000 in cash plus potential milestone and profit-share payments. The CEO’s post‑termination non‑compete was extended to 18 months.
Assertio Holdings, Inc. entered into a definitive agreement to be acquired by Garda Therapeutics through an all-cash tender offer at $18.00 per share, plus one contingent value right (CVR) per share. This values the equity at about $125.1 million, with the Board unanimously recommending stockholders tender their shares.
After the tender offer, a back-end merger will make Assertio a wholly owned subsidiary of Garda. The deal includes a 20-business-day “window-shop” period that lets Assertio evaluate superior proposals, with a reduced breakup fee for certain bidders. Closing requires a majority of shares tendered and at least $115,000,000 of Closing Net Cash.
Separately, Assertio sold all non-Rolvedon assets to Cosette Pharmaceuticals for $35,000,000 upfront plus potential milestones. CVR holders may receive additional cash tied to future SPRIX-related payments from Cosette, including delivery, 2026 profit-share, and 2027–2028 gross profit and sales milestones.
Assertio Holdings, Inc. entered into an Agreement and Plan of Merger to be acquired by Garda Therapeutics’ subsidiary for $18.00 per share in cash plus one contingent value right (CVR) per share. The Board unanimously approved the Merger and recommended stockholders tender their shares in the cash tender offer.
The Offer must begin within ten business days and initially runs for twenty business days. Purchaser’s obligation is subject to customary conditions, including at least a majority of shares validly tendered, the Company having $115,000,000 Closing Net Cash, and absence of prohibiting law. The Merger is not conditioned on financing; equity and debt commitments totaling up to $104,000,000 were delivered. Separately, Assertio sold specified product franchises to Cosette for $35,000,000 cash plus certain contingent and profit-share payments tied to SPRIX and other products.
Assertio Holdings, Inc. agreed to be acquired by Garda Therapeutics in an all-cash tender offer. Garda will offer $18.00 per share in cash, valuing the equity at approximately $125.1 million, plus one non-tradeable contingent value right (CVR) per share tied to future SPRIX milestones.
After the tender offer, Garda’s subsidiary will merge into Assertio, which will become a wholly owned subsidiary and delist from Nasdaq. Assertio simultaneously sold all non‑Rolvedon product franchises, including INDOCIN, SPRIX, SYMPAZAN, CAMBIA, ZIPSOR and OTREXUP, to Cosette Pharmaceuticals for $35 million upfront plus additional milestone and profit‑share payments, some of which will fund CVR payouts.
Assertion Holdings, Inc. ownership update: Nantahala Capital Management, LLC and its managers Wilmot B. Harkey and Daniel Mack report shared beneficial ownership of 692,335 shares of Common Stock as of March 31, 2026. The filing states this equals 10.74% of the class based on 6,445,161 shares outstanding reported in the issuer's Form 10-K filed March 16, 2026. The Reporting Persons disclaim sole voting or dispositive power and report only shared voting and disposition powers over the reported shares. A fund advised by Nantahala, Blackwell Partners LLC - Series A, is identified as having the right to receive dividends or sale proceeds on more than 5% of the reported holdings.
Assertio Holdings, Inc. is asking stockholders to vote at its May 5, 2026 virtual annual meeting on electing six directors, expanding its 2014 Omnibus Incentive Plan share pool, approving executive pay on an advisory basis, and ratifying Grant Thornton LLP as auditor.
The proxy highlights 2025 results including $117.1 million in product sales, with Rolvedon contributing $68.2 million, a GAAP net loss of $30.4 million, and non-GAAP adjusted EBITDA of $22.7 million. It also details leadership changes, stock ownership guidelines, a clawback policy and say‑on‑pay alignment with stockholder feedback.
Assertio Holdings, Inc. reports its 2025 results and strategic refocus on oncology, led by ROLVEDON. Net product sales were $117.1 million in 2025 versus $120.8 million in 2024, with ROLVEDON contributing $68.2 million, reflecting its role as the lead product.
The company divested Assertio Therapeutics on May 9, 2025, transferring opioid‑related legal liabilities, and advanced integration of products under Assertio Specialty. Large distributor purchases in 2025 shifted ROLVEDON sales timing, with minimal net product sales expected in early 2026 before normalized volumes in the second quarter.
Assertio recorded a net loss from operations of $21.5 million and used $28.2 million of operating cash flow in 2025, ending the year with $63.4 million in cash, cash equivalents and short‑term investments. A 1‑for‑15 reverse stock split was effected on December 26, 2025, and the company highlights reliance on a few large distributors and single‑source manufacturers as key risks.
Assertio Holdings reported mixed 2025 results, with net product sales of $117.1 million slightly below 2024, but non-GAAP adjusted EBITDA improving to $22.7 million from $18.3 million. The company still posted a larger GAAP net loss of $30.4 million, versus $21.6 million a year earlier.
Rolvedon remained the main growth driver with full-year net product sales of $68.2 million, while Sympazan rose and Indocin declined under generic pressure. For 2026, Assertio guides to net product sales between $110 million and $125 million and adjusted EBITDA between $28 million and $40 million, reflecting expectations for stronger profitability despite ongoing portfolio transitions.